We Offer Worldwide Shipping
Login Wishlist

Ziyuglycoside II

$225

  • Brand : BIOFRON

  • Catalogue Number : BF-Z1001

  • Specification : 98%

  • CAS number : 35286-59-0

  • Formula : C35H56O8

  • Molecular Weight : 604.8

  • PUBCHEM ID : 71773126

  • Volume : 20mg

In stock

Quantity
Checkout Bulk Order?

Catalogue Number

BF-Z1001

Analysis Method

HPLC,NMR,MS

Specification

98%

Storage

-20℃

Molecular Weight

604.8

Appearance

White crystal

Botanical Source

Ilex cornuta,Sanguisorba officinalis

Structure Type

Terpenoids

Category

Standards;Natural Pytochemical;API

SMILES

CC1CCC2(CCC3(C(=CCC4C3(CCC5C4(CCC(C5(C)C)OC6C(C(C(CO6)O)O)O)C)C)C2C1(C)O)C)C(=O)O

Synonyms

Urs-12-en-28-oic acid, 3-(α-L-arabinopyranosyloxy)-19-hydroxy-, (3β)-/zirconyl carbonate/(3β)-3-(α-L-Arabinopyranosyloxy)-19-hydroxyurs-12-en-28-oic acid/Ziyuglycoside II/Zirconium carbonate oxide

IUPAC Name

(1R,2R,4aS,6aR,6aS,6bR,8aR,10S,12aR,14bS)-1-hydroxy-1,2,6a,6b,9,9,12a-heptamethyl-10-[(2S,3R,4S,5S)-3,4,5-trihydroxyoxan-2-yl]oxy-2,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylic acid

Density

1.3±0.1 g/cm3

Solubility

Methanol; Ethanol; Hot water

Flash Point

218.6±26.4 °C

Boiling Point

716.2±60.0 °C at 760 mmHg

Melting Point

260-263℃

InChl

InChI=1S/C35H56O8/c1-19-10-15-35(29(39)40)17-16-32(5)20(27(35)34(19,7)41)8-9-23-31(4)13-12-24(30(2,3)22(31)11-14-33(23,32)6)43-28-26(38)25(37)21(36)18-42-28/h8,19,21-28,36-38,41H,9-18H2,1-7H3,(H,39,40)/t19-,21+,22+,23-,24+,25+,26-,27-,28+,31+,32-,33-,34-,35+/m1/s1

InChl Key

MFIXLWYJTVEVGO-YHGWSDCJSA-N

WGK Germany

RID/ADR

HS Code Reference

2932990000

Personal Projective Equipment

Correct Usage

For Reference Standard and R&D, Not for Human Use Directly.

Meta Tag

provides coniferyl ferulate(CAS#:35286-59-0) MSDS, density, melting point, boiling point, structure, formula, molecular weight etc. Articles of coniferyl ferulate are included as well.>> amp version: coniferyl ferulate

PMID

32097137

Abstract

Hepatocellular carcinoma (HCC) is a leading cause of cancer-related death worldwide. Phytochemicals are important candidates for developing anticancer agents. Ziyuglycoside II is a major active compound of Sanguisorba officinalis, which exhibits antiproliferation activity in several cancers; however, its action in HCC remains unknown. In this study, we investigated the antitumor activity of ziyuglycoside II against HCC and explored the potential mechanisms. We found that ziyuglycoside II exerts significant inhibitory effects on the viability and clonogenic activity of HCC cells. The proliferation repression mediated by ziyuglycoside II was mainly due to increased apoptosis and reactive oxygen species accumulation, as well as a G0/G1 phase cell-cycle arrest. Additionally, ziyuglycoside II markedly impaired HCC cell migration and invasion, two important steps during metastasis, and these suppressive effects may be attributed to the downregulation of matrix metalloproteinases MMP2 and MMP9 expression. Moreover, ziyuglycoside II blocked the epidermal growth factor receptor/nuclear factor kappa-B (EGFR/NF-kB) signaling, which may contribute to its anticancer activity. Taken together, our findings reveal antiproliferative and antimetastasis activities of ziyuglycoside II in HCC cells, implying that ziyuglycoside II might be a promising candidate for the development of novel anti-HCC drugs.

Title

Ziyuglycoside II Exerts Antiproliferative and Antimetastasis Effects on Hepatocellular Carcinoma Cells

Author

Wanqin Liao, Lixia Fan, Zhaoguang Zheng, Hui Liu, Huizhi Deng, Mingchan Li, Fang Liu, Anping Yang

Publish date

2020 Feb 22

PMID

31029785

Abstract

The development of chemopreventive approaches using natural products including phytochemicals is a potentially useful cancer treatment. The aims of this study were to examine the apoptotic effects of ziyuglycoside II, a major bioactive compound isolated from Sanguisorba officinalis L., on human colon cancer cells. The anticancer effect of ziyuglycoside II was examined in HCT116 (as p53 normal cells) and SW480 (as p53 mutant cells) colon cancer cells. Ziyuglycoside II treatment decreased HCT116 and SW480 cell proliferation. Cell death following ziyuglycoside II treatment was predominantly apoptosis but not cell cycle arrest. Apoptosis caused by p53 phosphorylation following ziyuglycoside II treatment in HCT116 cells involved activation of caspases, increased expression of BAX, mitochondrial cytochrome c and apoptosis inducing factor (AIF) release, while BCL-2 became down-regulated. In contrast, ziyuglycoside II treated SW480 cells displayed no change in phosphorylated-p53 and activation of caspases. Overall, these results suggest that ziyuglycoside II induces apoptosis through caspase-dependent and caspases-independent apoptosis, which was characterized by decreased expression of BCL-2, mitochondrial targeting, and altered production of ROS and translocation of AIF to the nuclei.

Title

Ziyuglycoside II Induces Caspases-Dependent and Caspases-Independent Apoptosis in Human Colon Cancer Cells

Author

Khaliunaa Lkhagvasuren 1 , Jin-Kyung Kim 2

Publish date

2019 Sep

PMID

31525383

Abstract

Triple negative breast cancer (TNBC), an aggressive form of breast cancer, has high rate of metastasis and which is the main cause of poor outcomes for such disease. The acquisition of invasive properties such as epithelial mesenchymal transition (EMT) and anoikis resistance is estimated to be the critical step in TNBC metastasis. Therefore, targeting these metastatic processes may contribute to the control of TNBC metastasis. In this study, investigations were conducted into the effect and mechanism of Ziyuglycoside II (Ziyu II), the main compound extracted from Sanguisorba Officinails L, on EMT, anoikis resistance as well as cell migration and invasion in human triple negative breast carcinoma MDA-MB-231 cells. The results showed that the treatment of Ziyu II could inhibit EMT, reverse anoikis resistance and subsequently suppress cell migration and invasion in MDA-MB-231 cells, which was associated with the inactivation of Src/EGFR-dependent ITGB4/FAK signaling and subsequent Akt and p38MAPK signaling pathways. These findings provide the new evidence of the anti-metastatic activity of Ziyu II and suggest the possibility of using this compound for the control of TNBC metastasis.

KEYWORDS

Metastasis; Src/EGFR-dependent ITGB4/FAK signaling; Triple negative breast cancer; Ziyuglycoside II.

Title

Ziyuglycoside II Suppresses the Aggressive Phenotype of Triple Negative Breast Cancer Cells Through Regulating Src/EGFR-dependent ITGB4/FAK Signaling

Author

Ke Wang 1 , Ping Zou 2 , Xue Zhu 1 , Ting Zhang 3

Publish date

2019 Dec


Description :

Ziyuglycoside II is a triterpenoid saponin compound extracted from Sanguisorba officinalis L.. Ziyuglycoside II induces reactive oxygen species (ROS) production and apoptosis. Anti-inflammation and anti-cancer effect[1].